Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $412.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research’s target price suggests a potential downside of 2.60% from the stock’s current price.

According to Zacks, “Regeneron’s third-quarter results were mixed, wherein earnings beat estimates by a significant margin but revenues fell short of expectations. However, the top line increased year over year. This was due to persistently strong contribution from Eylea in the U.S. and performance of the same in ex-U.S markets. Meanwhile, Regeneron has tightened U.S. Eylea net sales guidance for 2016. The company now expects U.S. Eylea net sales to grow 23–25% year over year, compared with its prior projection of 20–25% growth. Regeneron’s efforts to develop its pipeline are impressive. Moreover, Regeneron’s collaboration deals with companies like Bayer and Sanofi are encouraging. However, the company has recently suffered quite a few setbacks related to its pipeline. Sarilumab, which has blockbuster potential, got a CRL from the FDA. Regeneron heavy dependence on Eylea for growth is concerning given that Praluent sales are yet to pick up.”

Several other equities analysts have also recently issued reports on the company. Piper Jaffray Cos. set a $447.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, October 30th. Cowen and Company set a $430.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, October 30th. JPMorgan Chase & Co. set a $477.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, October 30th. Canaccord Genuity set a $450.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, November 6th. Finally, Leerink Swann set a $511.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, August 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $471.05.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 423.00 on Wednesday. The company has a 50-day moving average price of $380.16 and a 200-day moving average price of $387.18. The stock has a market cap of $44.34 billion, a price-to-earnings ratio of 61.72 and a beta of 1.79. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $592.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The company earned $1.22 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period last year, the business posted $3.47 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post $11.55 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of REGN. IFP Advisors Inc increased its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 326 shares in the last quarter. Alpha Windward LLC increased its stake in shares of Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $140,000. Finally, NEXT Financial Group Inc increased its stake in shares of Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 115 shares in the last quarter. Institutional investors and hedge funds own 68.32% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.